Pre and peri-operative erythropoeitin for reducing allogeneic blood transfusions in colorectal cancer surgery

Cochrane Database of Systematic Reviews

Volumn , Issue 2, 2008, Pages

  Devon, Karen M ^a   McLeod, R S ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLOOD TRANSFUSION; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; DRUG EFFICACY; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; PERIOPERATIVE PERIOD; PREOPERATIVE PERIOD; RETICULOCYTE COUNT; REVIEW; SYSTEMATIC REVIEW;

EID: 44949163687     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007148     Document Type: Review

References (22)

1. Adamson 1994 Adamson JW, Spivak JL. Physiological basis for the pharmacological use of recombinant human erythropoietin in surgery and cancer treatment. Surgery 1994;115:7-15.
2. Amato 2006 Amato A, Pescatori M. Perioperative blood transfusions for the recurrence of colorectal cancer. Cochrane Database of Systematic Reviews 2006, Issue 1 Art. No: CD005033. DOI.Art. No.:CD005033. DOI:10.1002/14651858.CD005033.pub2.
3. Beale 2005 Beale AL, Penney MD, Allison MC. The prevalence of iron deficiency among patients presenting with colorectal cancer. Colorectal Disease 2005;7(4):398-402.
4. Bohlius 2006 Bohlius J, Wilson J, Seidenfeld J, Piper M, Schwarzer G, Sandercock J, Trelle S, Weingart O, Bayliss S, Brunskill S, Djulbegovic B, Benett CL, Langensiepen S, Hyde C, Engert A. Erythropoietin or Darbepoetin for patients with cancer. Cochrane Database of Systematic Reviews 2006, Issue 3 Art. No.: CD003407. DOI:10.1002/14651858.CD003407.pub4..Art. No.: CD003407. DOI:10.1002/14651858.CD003407.pub4.
5. Braga 1995 Braga M, Gianotti L, et al.Evaluation of recombinant human erythropoietin to facilitate autologous blood donation before surgery in anaemic patients with cancer of the gastrointestinal tract. British Journal of Surgery 1995;82:1637.
6. Busch 1993 Busch OR, Hop WC, Marquet RL, Jeekel J. Prognostic impact of blood transfusions on disease-free survival in colorectal carcinoma. Scandinavian Journal of Gastroenterology - Supplement 1993;200:21-3.
7. Fisher 2003 Fisher JW. Erythropoietin: Physiology and Pharmacology Update. Experimental Biology and Medicine 2003;228:1-14.
8. Hansen 1995 Hansen E, Wolff N, et al.Tumor cells in blood shed from the surgical frield. Archives of Surgery 1995;130:387-393.
9. Henke 2003 Henke M, Laszig R, Ruebe C, Schaefer U, Haase KD, Schilcher B, et al.Erythropoeitin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
10. Hoynck v Papendrecht Hoynck van Papendrecht MAW, Hop W, Langenhorst BLAM, Kothe FC, Marquet RL, Jeekel J. Feasibility of a predeposit autologous blood donation program in colorectal cancer patients: results from a randomized clinical study. Vox Sanguinis 1992;62:102-107.
11. Jones 2004 Jones M, Schenkel B, et al.Epoeitin Alfa improves quality of life in patients with cancer. Cancer 2004;101:1720- 1732.
12. Laupacis 1993 Laupacis A, Canadian Orthopaedic Perioperative Erythropoeitin Study Group. Effectiveness of perioperative recombinant human erythropoeitin in hip replacement. Lancet 1993;341:1228-1232.
13. Laupacis 1998 Lapacis A, Fergusson D. Erythropoietin to minimize perioperative blood transfusion: a systematic review of randomized trials. Transfusion Medicine 1998;8:309-317.
14. Leyland-Jones 2003 Leyland-Jones B. Breast cancer trial with erythropoeitin terminated unexpectedly. Lancet Oncology 2003;4:459-460.
15. Miller 1990 Miller CB, Jones RL, et al.Decreased erythropoeitin response in patients with anemia of cancer. New England Journal of Medicine 1990;322:1689-1692.
16. Nielsen 1995 Nielsen. Detrimental effects of perioperative blood transfusion. British Journal of Surgery 1995;82:582-587.
17. Platanias 1991 Platanias LC, Miller CB, Mik R, et al.Treatment of chemotherapy-induced anemia with recombinant human erythropoeitin in cancer patients. Journal of Clinical Oncology 1991;9:2021-2026.
18. Scott 2002 Scott SN, Boeve TJ, McCullogh TM, Fitzpatrick KA, Karnell LH. The effects of Epoetin Alfa on transfusion requirements in head and neck cancer patients: A prospective, randomized, placebo-controlled study. The Laryngoscope 2002;112:1221-1229.
19. Tartter 1992 Tartter PI. The association of perioperative blood transfusion with colorectal cancer recurrence. Annals of Surgery 1992;216(6):633-638.
20. Van de Watering 2001 Van de Watering LMG, Brand A, Houbiers JGA, Klein Kranenbarg WM, Hermans J, Vande Velde CJH for the Cancer Recurrence and Blood transfusion study group. Perioperative blood transfusions, with or without allogeneic leucocytes, relate to survival, not to cancer recurrence. British Journal of Surgery 2001;88:267-272.
21. Vogelzang 1997 Vogelzang NJ, Breitbard W, Cella D, et al.Patients, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. Seminars in Hematology 1997;34:4-12.
22. Winearls 1986 Winearls CG, Oliver DO, et al.Effect of human erythropoeitin derived from recombinant DNA on the anemia of patients maintained by chronic hemodialysis. Lancet 1986;2:1175-1178.